Purchase Order 36C26025P0036

Award Date 10/8/24
Potential Completion Date 1/8/25
Potential Value $33K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Orlando, FL 32824, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $49,950.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections, to VA medical centers within the Veterans Integrated Service Network 20 (VISN 20). Profounda Inc. holds a...
The U.S. Department of Veterans Affairs (VA) has awarded a $49,950 firm fixed-price purchase order to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract is for the emergency delivery of 84 tablets of Impavido (Miltefosine) in three packages of 28, to the VA's Oklahoma City VA Medical Center (OKCVAMC) Pharmacy. This purchase order is part of a larger Blanket Purchase Agreement (BPA) valued at $1,127,000 that Profounda Inc. holds...
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $99,900.00, is for the delivery of Miltefosine 50mg tablets, a critical medication used to treat leishmaniasis and other drug-resistant infections. This purchase order is part of a larger $1,127,000 Blanket Purchase Agreement (BPA) held by Profounda Inc. with the VA's...
This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $96,000.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections, with a focus on providing emergency pharmaceutical solutions to veterans. Profounda Inc. has a...
This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Profounda Inc., a self-certified small disadvantaged business. The $49,950.00 contract is for the delivery of Profounda's Impavido/Miltefosine pharmaceutical product to the VA Sunshine Healthcare Network (VISN 20) in Orlando, Florida. Impavido/Miltefosine is used to treat leishmaniasis and other drug-resistant infections in veterans. This award is the latest in a...
The Department of Veterans Affairs' Veterans Health Administration awarded a firm fixed-price purchase order to Profounda Inc., a self-certified small disadvantaged business, to provide Miltefosine drug with a potential value of $149,950.00. The order, placed under the VHA's Veterans Integrated Service Network 23, supports the agency's mission to deliver healthcare services to veterans by ensuring access to this specialized pharmaceutical product needed for treatment. Profounda has previously...
The U.S. Department of Veterans Affairs (VA) Veterans Health Administration awarded a $299,700.00 firm fixed-price purchase order to Profounda Inc., a self-certified small disadvantaged business manufacturer of pharmaceutical products, to provide the medication Impavido (miltefosine) to the Puget Sound VA Medical Center. This sole-source procurement is to acquire this specialized drug for treating Disseminated Cutaneous Acanthamboeba, with a performance period from May 1, 2025, to October 30,...
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) Clinical Center to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products, for $112,000.00. The contract, which does not have a set-aside designation, is for the delivery of Profounda's pharmaceutical products, with a period of performance through September 19, 2023. Profounda has been awarded numerous...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $67,932.00 contract is for the delivery of Impavido 50 mg capsule medical supplies to support the recurring medical needs of military health facilities. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) under the DLA's SPE2DB program, which allows the...
This is a $132,222 firm fixed-price purchase order awarded by the Department of Veterans Affairs to United Drug Supply Inc., a woman-owned small business. The contract is not set aside. United Drug Supply Inc. specializes in providing medical supplies and equipment to the federal government, primarily the Department of Defense and Department of Veterans Affairs. The contract involves the delivery of various medical consumables, diagnostic devices, and pharmaceutical products to support...

This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $33,300.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections. The contract has an ultimate completion date of January 8, 2025.

Profounda Inc. has a significant Blanket Purchase Agreement (BPA) with the VA's Veterans Health Administration, specifically with Veterans Integrated Service Network (VISN) 8, valued at $1,127,000. This BPA, established on July 1, 2020, and running through June 30, 2025, allows the company to pre-position Impavido/Miltefosine at VA medical centers within the network, enabling expedited access and treatment for urgent cases. This Indefinite Delivery Vehicle (IDV) facilitates rapid procurement of Profounda's specialized pharmaceutical product without typical procurement delays, highlighting the company's critical role in providing emergency medical solutions to the VA healthcare system.

Generated 4/5/25, 9:44 AM